Tirzepatide Matches Competitor's Cardioprotective Benefits for Diabetics

(MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide (Trulicity) in patients with type 2 diabetes and atherosclerotic cardiovascular disease, a large…

Source link : https://www.medpagetoday.com/cardiology/prevention/119074

Author :

Publish date : 2025-12-17 22:47:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Tirzepatide Matches Competitor’s Cardioprotective Benefits for Diabetics

Gout and Its Comorbidities

The Food Chain – What is the ultimate hangover cure?

Related Posts

Is this carved rock an ancient Roman board game?

Paradigm Shift for Evaluating, Treating Biochemical Recurrence in Prostate Cancer

Simple Question May Help Identify Women With Urinary Incontinence

NYC RNs Reach a Deal to End Strike at 2 Hospitals; Walkout Continues at Another

Daily Coffee Tied to Brain Benefits

Statin Adverse Event Labels May Be Overcautious, Analysis Suggests

Is this carved rock an ancient Roman board game?

Paradigm Shift for Evaluating, Treating Biochemical Recurrence in Prostate Cancer

Simple Question May Help Identify Women With Urinary Incontinence

NYC RNs Reach a Deal to End Strike at 2 Hospitals; Walkout Continues at Another

Daily Coffee Tied to Brain Benefits

Statin Adverse Event Labels May Be Overcautious, Analysis Suggests

Catherine O’Hara’s Cause of Death Revealed

Cladribine a Safe ‘Exit Strategy’ for Stopping DMTs for MS

Categories

Archives